Sanofi Profit Beats Estimates With New CEO Hudson at Helm
This article is for subscribers only.
Sanofi’s key growth driver, a drug for eczema and asthma, helped the French pharma giant report earnings that beat analysts’ estimates in Paul Hudson’s first quarter as chief executive officer.